Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: A phase I/II controlled, adaptively randomized study

Journal of Clinical Oncology

Volumn 29, Issue 3, 2011, Pages 294-302

  Parmar, Simrit ^a   Andersson, Borje S ^a   Couriel, Daniel ^a   Munsell, Mark F ^a   Fernandez Vina, Marcelo ^a   Jones, Roy B ^a   Shpall, Elizabeth J ^a   Popat, Uday ^a   Anderlini, Paolo ^a   Giralt, Sergio ^a   Alousi, Amin ^a   Cano, Pedro ^a   Bosque, Doyle ^a   Hosing, Chitra ^a   De Padua Silva, Leandro ^a   Westmoreland, Michael ^a   Wathen, J Kyle ^a   Berry, Donald ^a   Champlin, Richard E ^a   De Lima, Marcos J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CLOFARABINE; CYTARABINE; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; MELPHALAN; METHOTREXATE; PENTOSTATIN; TACROLIMUS;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANCER SURVIVAL; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADENOSINE DEAMINASE INHIBITORS; ADOLESCENT; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG TOXICITY; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTENTION TO TREAT ANALYSIS; MALE; METHOTREXATE; MIDDLE AGED; PENTOSTATIN; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION CONDITIONING;

EID: 79951961317     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.30.6357     Document Type: Article

References (24)

1. Hurley CK, Baxter Lowe LA, Logan B, et al: National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplants. Biol Blood Marrow Transplant 9:610-615, 2003 (Pubitemid 38351780)
2. Madrigal JA, Scott I, Arguello R, et al: Factors influencing the outcome of bone marrow transplants using unrelated donors. Immunol Rev 157:153-166, 1997 (Pubitemid 27303127)
3. Ho VT, Kim HT, Liney D, et al: HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 37:845-850, 2006
4. Flomenberg N, Baxter-Lowe LA, Confer D, et al: Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 104:1923-1930, 2004
5. Lee SJ, Klein J, Haagenson M, et al: High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110:4576-4583, 2007 (Pubitemid 351377826)
6. Teshima T, Matsuo K, Matsue K, et al: Impact of human leucocyte antigen mismatch on graft-versus-host disease and graft failure after reduced intensity conditioning allogeneic haematopoietic stem cell transplantation from related donors. Br J Haematol 130:575-587, 2005 (Pubitemid 43899762)
7. Goulmy E, Schipper R, Pool J, et al: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 334:281-285, 1996 (Pubitemid 26033083)
8. Ratanatharathorn V, Nash RA, Przepiorka D, et al: Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92:2303-2314, 1998 (Pubitemid 28452971)
9. Bolaños-Meade J, Jacobsohn DA, Margolis J, et al: Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 23:2661-2668, 2005 (Pubitemid 46179455)
10. Jacobsohn DA, Chen AR, Zahurak M, et al: Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 25:4255-4261, 2007 (Pubitemid 47548565)
11. Higman M, Vogelsang GB, Chen A: Pentostatin: Pharmacology, immunology, and clinical effects in graft-versus-host disease. Expert Opin Pharmacother 5:2605-2613, 2004 (Pubitemid 39646522)
12. Epstein J, Bealmear PM, Kennedy DW, et al: Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2′-deoxycoformycin. Exp Hematol 14:845-849, 1986 (Pubitemid 17180037)
13. Aye MT, Dunne JV: Effect of 2′-deoxycoformycin on erythroid, granulocytic, and T-lymphocyte colony growth. Blood 58:1043-1046, 1981 (Pubitemid 12227948)
14. Jacobsohn DA, Gilman AL, Rademaker A, et al: Evaluation of pentostatin in corticosteroidrefractory chronic graft-versus-host disease in children: A Pediatric Blood and Marrow Transplant Consortium study. Blood 114:4354-4360, 2009
15. Alousi AM, Weisdorf DJ, Logan BR, et al: Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: A randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 114:511-517, 2009
16. Przepiorka D, Weisdorf D, Martin P, et al: 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825-828, 1995
17. Parmar S, Del Lima M, Zou Y, et al: Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114:2884-2887, 2009
18. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
19. Gooley TA, Leisenring W, Crowley J, et al: Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 18:695-706, 1999 (Pubitemid 29126745)
20. Leach JW, Pham T, Diamandidis D, et al: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) following treatment with deoxycoformycin in a patient with cutaneous T-cell lymphoma (Sezary syndrome): A case report. Am J Hematol 61:268-270, 1999 (Pubitemid 29355026)
21. Estey E: Do commonly used clinical trial designs reflect clinical reality? Haematologica 94:1435-1439, 2009
22. Martin PJ, Bachier CR, Klingemann HG, et al: Endpoints for clinical trials testing treatment of acute graft-versus-host disease: A joint statement. Biol Blood Marrow Transplant 15:777-784, 2009
23. de Lima M, Couriel D, Thall PF, et al: Oncedaily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 104:857-864, 2004 (Pubitemid 38970585)
24. Margolis J, Grever MR: Pentostatin (Nipent): A review of potential toxicity and its management. Semin Oncol 27:9-14, 2000 (Pubitemid 30422427)